- Federal government must find alternatives to rescheduling hydrocodone combination drugs
- FDA to recommend rescheduling of opioid painkiller hydrocodone from CIII to CII
- Mallinckrodt receives FDA approval for Xartemis XR
- QRxPharma refiles application for oxycodone, morphine combination pill Moxduo
- FDA approves first single-entity, extended-release hydrocodone drug
PARSIPPANY, N.J. — The Food and Drug Administration has approved a drug for opioid dependence made by Actavis, the company said.
Actavis announced the approval of buprenorphine hydrochloride and naloxone hydrochloride dehydrate sub-lingual tablets in the 2 mg/0.5 mg and 8 mg/2 mg strengths.
The drug is a generic version of Reckitt Benckiser's Suboxone, which had sales of about $625 million in 2012, according to IMS Health.